An estimates-beating set of preliminary financial numbers and two bullish analyst updates weren't enough to lift Madrigal Pharmaceuticals (MDGL -0.59%) stock out of the doldrums over the past few trading days. Investor expectations are clearly very high, as the company's share price had withered by nearly 20% week to date as of Friday before market open, according to data compiled by S&P Global Market Intelligence.Preliminary numbers revealedMadrigal unveiled those figures Monday morning. The company said t ...

Shares of Madrigal Pharmaceuticals (MDGL) lost 9.7% on Tuesday as the investors were not impressed by its preliminary fourth-quarter and full-year 2024 results. The company’s top line comprises only its product revenues. Madrigal’s commercial portfolio has one marketed drug, Rezdiffra (resmetirom), a once-daily, oral and liver-directed THR-β agonist.Rezdiffra gained the FDA’s accelerated approval in March 2024 for adult patients with nonalcoholic steatohepatitis (NASH). Subsequently, the drug became the fir ...

Shares of Madrigal Pharmaceuticals (MDGL -13.31%) were sinking 13.3% lower as of 11:11 a.m. ET on Monday. The sell-off came after the drugmaker announced its preliminary fourth-quarter and full-year 2024 results. Madrigal reported preliminary Q4 net sales for its metabolic steatohepatitis (MASH) drug Rezdiffra of between $100 million and $103 million. The company announced preliminary full-year 2024 net sales of the drug of between $177 million and $180 million. Madrigal also stated that it should end 2024 ...

(Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 MADRIGAL PHARMACEUTICALS, INC. Delaware 001-33277 04-3508648 (State or other jurisdiction of incorporation) Four Tower Bridge 200 Barr Harbor Drive, Suite 200 West Conshohocken, Pennsylvania 19428 (Address of principal exec ...

Business Performance and Financial Updates - Preliminary fourth-quarter 2024 Rezdiffra net sales range between $100 million to $103 million, and full-year 2024 net sales range between $177 million to $180 million [4][5] - Preliminary year-end 2024 cash, cash equivalents, restricted cash, and marketable securities total approximately $931 million [4][5] - Over 11,800 patients were on Rezdiffra therapy as of year-end 2024 [4][5][13] Key Milestones and Achievements - Rezdiffra received U.S. FDA approval on March 14, 2024, becoming the first and only approved therapy for MASH [5] - The Phase 3 MAESTRO-NASH trial results were published in The New England Journal of Medicine and recognized as one of the 14 notable scientific research articles of 2024 [5] - EMA validated the Marketing Authorization Application (MAA) for Rezdiffra on March 5, 2024, with an anticipated decision in mid-2025 and a potential European launch starting in Germany in the second half of 2025 [5] - Enrollment for the MAESTRO-NASH OUTCOMES study, evaluating Rezdiffra in patients with compensated MASH cirrhosis, was completed on October 21, 2024 [5] Market Opportunity and Disease Overview - MASH is a serious liver disease that can progress to cirrhosis, liver failure, liver cancer, and premature mortality, and is expected to become the leading cause of liver transplantation in the U.S. [3][6] - Patients with moderate to advanced liver fibrosis (stages F2 to F3) have a 10-17 times higher risk of liver-related mortality compared to those without fibrosis, while those with cirrhosis face a 42 times higher risk [6] - An estimated 1.5 million patients in the U.S. have been diagnosed with MASH, with approximately 315,000 patients under the care of liver specialists having moderate to advanced fibrosis [7] Strategic Outlook and Growth Opportunities - The company is preparing for European expansion in the second half of 2025, pending EMA approval [5][13] - Positive results from the MAESTRO-NASH OUTCOMES trial could position Rezdiffra as the only treatment for F2 to F4 MASH and the only therapy with outcomes data this decade [13] Leadership and Communication - Bill Sibold, CEO of Madrigal, will present updates at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025, via a live webcast [2][4]

Preliminary fourth-quarter and full-year 2024 Rezdiffra™ (resmetirom) net sales ranges of $100 million to $103 million and $177 million to $180 million, respectivelyPreliminary year-end 2024 cash, cash equivalents, restricted cash and marketable securities of approximately $931 millionAs of year-end 2024, more than 11,800 patients on RezdiffraMadrigal to present at the 43rd Annual J.P. Morgan Healthcare Conference at 2:15 p.m. PST (5:15 p.m. EST) on Wednesday January 15, 2025 CONSHOHOCKEN, Pa., Jan. 13, 20 ...

When I last covered Madrigal Pharmaceuticals (NASDAQ: MDGL ) in April 2024, I predicted a strong launch for Rezdiffra (resmetirom) in metabolic-associated steatohepatitis (MASH). The stock is up over 60% since that article with the first two quarters of Rezdiffra sales beating estimates. There haveScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, ...

Company Presentation - Madrigal Pharmaceuticals will present at the 43rd Annual J P Morgan Healthcare Conference on January 15 2025 at 2 15 pm PT [1] - The presentation will be webcast live and accessible via Madrigalâs Investor Relations Site Events and Presentations [1] Company Overview - Madrigal Pharmaceuticals is a biopharmaceutical company focused on developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) a liver disease with significant unmet medical needs [2] - The companyâs lead medication Rezdiffra (resmetirom) is a once-daily oral liver-directed THR-β agonist designed to target key underlying causes of MASH [2] Contact Information - Investor inquiries can be directed to Tina Ventura at IR@madrigalpharma com [3] - Media inquiries can be directed to Christopher Frates at media@madrigalpharma com [3]

Madrigal Pharmaceuticals, Inc. (MDGL) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, MDGL's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross."A golden cross is a technical chart pattern that can signify a potential bullish breakout. It's formed from a crossover involving a security's short-term moving average breaking above a longer-term moving average, with the most common moving av ...

Shares of Madrigal (MDGL) have gained 34.6% over the past four weeks to close the last trading session at $288.58, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $364.87 indicates a potential upside of 26.4%.The average comprises 15 short-term price targets ranging from a low of $155 to a high of $507, with a standard deviation of $81.13. While the lowest estimate indicates a d ...